Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Actemra Production Has Doubled Since Start of COVID-19 Pandemic: Chugai CEO
December 22, 2021
- Healios, Hiroshima Univ. to Collaborate on Cancer Immunotherapy Using Gene-Edited NK Cells
December 22, 2021
- Daiichi Espha Rolls Out Authorized Generics for Artist, Sunrythm
December 21, 2021
- RaQualia Grants Global License for Chronic Pain Drug to Hisamitsu
December 21, 2021
- Takeda’s Vedolizumab Grabs EU Panel Nod for Chronic Pouchitis
December 21, 2021
- Astellas’ Padcev Gets Key European Backing for Bladder Cancer
December 21, 2021
- Shionogi’s Oral COVID-19 Drug Shows High Activity against Omicron
December 21, 2021
- Alnylam Seeks Japan Approval for Vutrisiran for FAP
December 21, 2021
- Mitsubishi Tanabe, 4 Partners Develop AI-Based Protein Crystal Structure Evaluation Technology
December 21, 2021
- Japan’s Dementia/MCI Market to Exceed 400 Billion Yen in 2030: Fuji Keizai
December 21, 2021
- Sosei to Get £5 Million Milestone Payment from GSK as GI Drug Program Progresses
December 21, 2021
- Eisai Snags Rights to Gilead’s JAK Inhibitor Jyseleca in 4 Asian Markets
December 21, 2021
- Biogen Halves US Price Tag on Aduhelm to Improve Patient Access
December 21, 2021
- Astellas to Abolish Pay Structure for Sales Reps, Switching to Company-Wide System Next April
December 20, 2021
- Sosei, Twist Bioscience Hook Up on GPCR Antibodies
December 20, 2021
- Medicago Submits Final Vaccine Data for Canada’s COVID-19 Rolling Review
December 20, 2021
- Pfizer Agrees to Supply Oral COVID-19 Drugs for 2 Million People in Japan
December 20, 2021
- Nikhilesh Kalra to Head Up Sanofi’s Japan Consumer Unit from January
December 20, 2021
- Biogen to Challenge European Rejection of Aducanumab
December 20, 2021
- Otsuka Grabs Rights to Kyoto University Spinoff’s iPSC-Derived CAR-T/TCR-T Production Techs
December 17, 2021
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…